Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Singapore S.E.
Equities
T14
CNE100000924
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | 0.00% | +0.50% | -3.38% |
04-30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
04-30 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Recommends Dividend | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The firm trades with high earnings multiples: 22.97 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.38% | 3.16B | C | ||
+39.33% | 6.11B | B- | ||
-18.38% | 4.35B | C+ | ||
-9.17% | 3.18B | B- | ||
-3.41% | 2.51B | - | D+ | |
+48.74% | 1.98B | - | ||
-4.82% | 1.74B | - | - | |
-1.24% | 1.63B | - | - | |
-8.96% | 1.6B | C- | ||
+39.87% | 1.44B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600329 Stock
- T14 Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited